REGENXBIO Past Earnings Performance

Past criteria checks 0/6

REGENXBIO's earnings have been declining at an average annual rate of -26.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 15.7% per year.

Key information

-26.4%

Earnings growth rate

-23.5%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	15.7%
Return on equity	-84.5%
Net Margin	-292.0%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Oct 03

Regenxbio: A Transformative Year

Sep 15

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Aug 29

Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%

Aug 03

Regenxbio: Patience And Regular Homework Are Keys

Jul 12

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Slashed This Year's Estimates

Jun 27

The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business

May 12

Regenxbio: Is The Ultimate Catalyst Coming?

Apr 20

Revenue & Expenses Breakdown
Beta

How REGENXBIO makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:RGNX Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	90	-263	88
30 Sep 23	99	-261	91
30 Jun 23	97	-274	88
31 Mar 23	110	-270	86
31 Dec 22	113	-280	85
30 Sep 22	480	74	78
30 Jun 22	484	91	84
31 Mar 22	474	101	81
31 Dec 21	470	128	77
30 Sep 21	93	-212	81
30 Jun 21	161	-145	78
31 Mar 21	156	-121	75
31 Dec 20	155	-111	71
30 Sep 20	145	-91	69
30 Jun 20	61	-135	57
31 Mar 20	52	-103	55
31 Dec 19	35	-95	52
30 Sep 19	64	-64	48
30 Jun 19	55	-49	45
31 Mar 19	87	-37	40
31 Dec 18	219	100	37
30 Sep 18	180	80	31
30 Jun 18	176	78	31
31 Mar 18	142	53	29
31 Dec 17	10	-73	27
30 Sep 17	10	-77	28
30 Jun 17	9	-74	25
31 Mar 17	5	-74	25
31 Dec 16	5	-63	24
30 Sep 16	7	-49	22
30 Jun 16	8	-38	18
31 Mar 16	7	-32	16
31 Dec 15	8	-24	12
30 Sep 15	4	-21	9
30 Jun 15	4	-16	7
31 Mar 15	4	-8	5
31 Dec 14	6	-5	4
31 Dec 13	6	-6	5

Quality Earnings: RGNX is currently unprofitable.

Growing Profit Margin: RGNX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RGNX is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.

Accelerating Growth: Unable to compare RGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).

Return on Equity

High ROE: RGNX has a negative Return on Equity (-84.52%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

REGENXBIO Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

President exercised options and sold US$216k worth of stock

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

President exercised options and sold US$272k worth of stock

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Price target increased by 7.3% to US$38.55

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

Consensus EPS estimates fall by 21%

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

President exercised options and sold US$195k worth of stock

REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

President notifies of intention to sell stock

REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Consensus revenue estimates fall by 16%

Executive VP & Chief Medical Officer notifies of intention to sell stock

President notifies of intention to sell stock

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Price target decreased by 10% to US$36.40

REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial

Consensus EPS estimates upgraded to US$4.84 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio

REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202

REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181

Consensus EPS estimates fall by 19%

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

Consensus EPS estimates upgraded to US$4.26 loss

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 21%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

REGENXBIO Inc. Announces Executive Promotions

Executive VP & Chief Medical Officer notifies of intention to sell stock

REGENXBIO Inc. Reports Update on Advancement of Programs for CLN2 Disease

Regenxbio Announces Completion of Dosing in the Phase I/Ii Trial of Rgx-111 for the Treatment of Severe Mps I

Price target decreased to US$44.70

Consensus revenue estimates fall by 14%

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

REGENXBIO Inc. Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE(R) Trial of Rgx-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Investor sentiment improved over the past week

Regenxbio: A Transformative Year

Regenxbio Inc. Announces Additional Positive Interim Data from the Phase I/Ii/Iii Campsiite™ Trial of Rgx-121 for the Treatment of Patients Up to 5 Years Old Diagnosed with Mucopolysaccharidosis Type Ii (Mps Ii), Also Known as Hunter Syndrome

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Executive VP & Chief Financial Officer notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II

Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%

Executive VP & Chief Financial Officer recently sold US$144k worth of stock

Regenxbio: Patience And Regular Homework Are Keys

Revenue & Expenses Breakdown
Beta